Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer
Ujjwal Mukund Mahajan(Medi-Caps University), Julia Mayerle(LMU Klinikum), Gunnar Glöckl(Universität Greifswald), Matthias Evert(University of Regensburg), Norbert Hosten(Universitätsmedizin Greifswald), Werner Weitschies(Universitätsmedizin Greifswald), Theresa Schwaiger(University of Graz), Frank Dombrowski(Universität Greifswald), Raghavendra Palankar(Universitätsmedizin Greifswald), Matthias Sendler(Universitätsmedizin Greifswald), Mihaela Delcea(Universitätsmedizin Greifswald), Jens‐Peter Kühn(Universitätsmedizin Greifswald), Steffen Teller(Universität Greifswald), Silvia Ribback(Friedrich-Loeffler-Institut), Cindy van den Brandt(Universitätsmedizin Greifswald), Markus M. Lerch(Ludwig-Maximilians-Universität München), Frank Ulrich Weiß(Universitätsmedizin Greifswald)
Cited by 97
Related Papers
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Cohort Profile: The Study of Health in Pomerania
|International Journal of Epidemiology|2010|1k
ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries
|Translational Psychiatry|2020|702
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698
Clinical and genetic characteristics of hereditary pancreatitis in Europe
|Clinical Gastroenterology and Hepatology|2004|615